Neuropace Inc Cash Flow Conversion Efficiency
Neuropace Inc cash flow conversion efficiency. Based on the latest financial reports, Neuropace Inc (NPCE) has a cash flow conversion efficiency ratio of -0.328x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.90 Million) by net assets ($11.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neuropace Inc (2019–2025)
Cash flow conversion efficiency of Neuropace Inc from 2019 to 2025. This chart illustrates how Neuropace Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Neuropace Inc stock quote for real-time trading data and today's change.
Neuropace Inc Cash Flow Conversion Ratio Explained
Neuropace Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neuropace Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuropace Inc ranked by their cash flow conversion efficiency. Also see Neuropace Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Binh Minh Plastics JSC
VN:BMP
|
-0.066x |
|
Shenzhen TVT Digital Technology Co Ltd
SHE:002835
|
0.032x |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
0.037x |
|
Chung Hwa Pulp Corp
TW:1905
|
-0.002x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
InBody Co.Ltd
KQ:041830
|
0.032x |
|
Pes Camanchaca
SN:CAMANCHACA
|
0.052x |
|
ValueHD Corp. A
SHE:301318
|
0.002x |
Annual Cash Flow Conversion Efficiency for Neuropace Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neuropace Inc from 2019 to 2025. Review how much free cash does Neuropace Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $19.03 Million | $-11.01 Million | -0.578x | +74.18% |
| 2024-12-31 | $8.01 Million | $-17.95 Million | -2.240x | -134.83% |
| 2023-12-31 | $20.65 Million | $-19.70 Million | -0.954x | +10.03% |
| 2022-12-31 | $34.78 Million | $-36.87 Million | -1.060x | -217.06% |
| 2021-12-31 | $73.50 Million | $-24.58 Million | -0.334x | -328.75% |
| 2020-12-31 | $-147.83 Million | $-21.61 Million | 0.146x | -24.45% |
| 2019-12-31 | $-129.35 Million | $-25.03 Million | 0.193x | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more